These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Methotrexate for relapse of metastatic non-seminomatous germ-cell tumours. Atkinson CH; Horwich A; Peckham MJ Med Oncol Tumor Pharmacother; 1987; 4(1):33-7. PubMed ID: 3037206 [TBL] [Abstract][Full Text] [Related]
83. VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC). Madrigal PA; Manga GP; Palomero I; Gomez RG Cancer Chemother Pharmacol; 1982; 7(2-3):203-4. PubMed ID: 6282485 [No Abstract] [Full Text] [Related]
84. Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy. Harper PG; Dally MB; Geddes DM; Spiro SG; Smyth JF; Souhami RL Cancer Chemother Pharmacol; 1982; 7(2-3):179-80. PubMed ID: 6282480 [TBL] [Abstract][Full Text] [Related]
85. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma. Schell FC; Yap HY; Hortobagyi GN; Issell B; Esparza L Cancer Chemother Pharmacol; 1982; 7(2-3):223-5. PubMed ID: 7083463 [No Abstract] [Full Text] [Related]
86. VP16-213 as a single agent in advanced testicular tumors. Fitzharris BM; Kaye SB; Saverymuttu S; Newlands ES; Barrett A; Peckham MJ; McElwain TJ Eur J Cancer (1965); 1980 Sep; 16(9):1193-7. PubMed ID: 7227446 [No Abstract] [Full Text] [Related]
87. The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma. Newlands ES; Bagshawe KD Cancer Chemother Pharmacol; 1982; 7(2-3):211-4. PubMed ID: 7083462 [TBL] [Abstract][Full Text] [Related]
88. Mitomycin is active against refractory germ-cell tumors. A phase II study. Hoskins P; Coppin CM; Murray N Am J Clin Oncol; 1990 Feb; 13(1):35-8. PubMed ID: 2154922 [TBL] [Abstract][Full Text] [Related]
89. Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia. Look AT; Dahl GV; Rivera G; Mauer AM Cancer Chemother Pharmacol; 1982; 7(2-3):161-7. PubMed ID: 6177437 [No Abstract] [Full Text] [Related]
90. Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer. Perez Manga G; Madrigal Alonso PL; Alburquerque Carbuccia H Cancer Chemother Pharmacol; 1982; 7(2-3):227-9. PubMed ID: 6805972 [No Abstract] [Full Text] [Related]
91. Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A Gynecologic Oncology Group Study. Morrow CP; Bundy BN; Hoffman J; Sutton G; Homesley H Am J Clin Oncol; 1986 Feb; 9(1):24-6. PubMed ID: 3006473 [TBL] [Abstract][Full Text] [Related]
92. VP16-213 (etoposide). A critical review of its activity. Cavalli F Cancer Chemother Pharmacol; 1982; 7(2-3):81-5. PubMed ID: 7044594 [No Abstract] [Full Text] [Related]
93. Etoposide in the treatment of refractory breast cancer. Höffken K Cancer Treat Rev; 1982 Jun; 9 Suppl():63-6. PubMed ID: 7127336 [No Abstract] [Full Text] [Related]
94. Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Nitschke R; Starling KA; Vats T; Bryan H Med Pediatr Oncol; 1978; 4(2):127-32. PubMed ID: 275532 [TBL] [Abstract][Full Text] [Related]
95. A radioimmunoassay for VP16-213 in plasma. Aherne GW; Marks V Cancer Chemother Pharmacol; 1982; 7(2-3):117-21. PubMed ID: 7083451 [TBL] [Abstract][Full Text] [Related]
96. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Einhorn LH Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S45-50. PubMed ID: 3815718 [TBL] [Abstract][Full Text] [Related]
97. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Henwood JM; Brogden RN Drugs; 1990 Mar; 39(3):438-90. PubMed ID: 2184009 [No Abstract] [Full Text] [Related]